TITLE

TREATMENT OF ZERO AND INTERMEDIATE TPMT PATIENTS WITH A TAILORED DOSE OF AZATHIOPRINE

AUTHOR(S)
Ansari, A.; Escudier, M.; Marinaki, A.; Yim, A.; Hirst, J.; Duley, J.; Sanderson, J.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA64
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Deficiency of thiopurine methyl transferase (TPMT) is associated with a high risk of adverse effects on azathioprine (AZA) therapy. Conventionally, AZA is avoided in patients with zero TPMT (1 in 300) and those with heterozygous TPMT deficiency. (1 in 10). Aims: We have studied the outcome of TPMT deficient patients receiving a tailored Iow dose of AZA. Methods: According to a department protocol, patients with zero TPMT were offered treatment with 5% usual dose, heterozygotes with 1 mg/kg AZA. Thioguanine nucleotide (TGN) levels were assayed in a proportion of cases. In addition, a questionnaire was sent to physicians regarding the outcome of patients referred for TPMT assay from outside the author's institution. Results: Two patients with zero TPMT (One CD, one UC) responded to 5% dosing with a prompt and full clinical remission (HBI / Truelove and Witts score). Both have remained in steroid-free remission for two years. TGN levels were very high yet both remained free of myelotoxicity. 26 heterozygotes 12 CD, 7 UC, 2 autoimmune hepatitis, and 5 with oral ulceration were treated. 20 (77%) patients responded to treatment, 1 did not respond and 5 withdrew treatment as a consequence of side effects (19%). TGN levels were variable and did not correlate with response or side effects. Of 92 questionnaires sent, 51 replies were obtained. Of these, only 15 patients started azathioprine at 1 mg/kg. 11/15 (73%) responded to treatment, 2 failed, and 2 withdrew due to side effects. In 36/51 (71%) the requesting physician decided not to use ozathioprine due to the Iow TPMT level. Conclusions: Physicians generally avoid AZA in patients with TPMT deficiency. However, the results of this study show that heterozygous patients respond well to Iow dose AZA. Furthermore, zero TPMT patients can be successfully treated with a very Iow dose of AZA.
ACCESSION #
9747725

 

Related Articles

  • NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p616 

    The article presents information on nucleotide reverse transcriptase inhibitors, which are antiviral drugs, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • Malaria prophylaxis October 20, 2003.  // Pulse;10/20/2003, Vol. 63 Issue 42, p82 

    Provides information on malaria prophylaxis. Revised malaria guidelines in Great Britain; Recommended medications for patients with malaria; Doses of antimalarial prophylactics for children.

  • How Your Doctor Determines Your Dosage. Dunkin, Mary Anne // Arthritis Today;Jul/Aug99, Vol. 13 Issue 4, p44 

    Discusses the factors considered by doctors in determining the range of medication dosages for a particular illness. Factor that doctors consider when prescribing medications for children; Dosage of prednisone used to control acute joint inflammation; Dosage of prednisone required to control...

  • Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p29 

    Presents results of a study which compares standard aminoglycoside administration with once-a-day dosing among 1625 immunocompetent, infected adults. Bacteriologic cure rates; Decreased nephrotoxicity among patients given a once-a-day therapy.

  • Single or multiple daily doses of aminoglycosides: A meta-analysis. Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p29 

    Presents results of a study which compares single with multiple daily doses of aminoglycosides and which involved children and neutropenic cancer patients, most of whom were without preexisting renal disease.

  • A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily... Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p30 

    Presents meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. Absence of significant difference in bacteriologic efficacy or nephrotoxicity between the two dosing schedules; Ototoxicity rates.

  • Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. Crane, John K. // Cortlandt Forum;06/25/97, Vol. 10 Issue 6, p30 

    Presents a meta-analysis of the effectiveness and safety of once-daily dosage of aminoglycosides. Inclusion of studies in which aminoglycosides were administered for prophylaxis; Decreased nephrotoxicity; Comments on the meta-analysis include those on the duration of treatment and the method...

  • Validation of a Proposed Warfarin Dosing Algorithm Based on the Genetic Make-Up of Egyptian Patients. Ekladious, Sherif M. M.; Issac, Marianne Samir M.; Sharaf, Sahar Abd El-Atty; Abou-Youssef, Hazem S. // Molecular Diagnosis & Therapy;Dec2013, Vol. 17 Issue 6, p381 

    Background: Warfarin is the most frequently prescribed oral anticoagulant worldwide. Due to its narrow therapeutic index and inter-patient variability in dose requirement, this drug has been considered an ideal target for personalised medicine. Several warfarin dosing algorithms have been...

  • 76P A PHASE 1 OPEN-LABEL FIXED-SEQUENCE TWO-PERIOD CROSSOVER STUDY OF THE EFFECT OF MULTIPLE DOSES OF TAMOXIFEN ON PALBOCICLIB (PD-0332991) PHARMACOKINETICS IN HEALTHY MALE VOLUNTEERS. Hoffman, J.T.; O'Gorman, M.; Loi, C.; Plotka, A.; Kirkovsky, L.; Boutros, T.; Stampino, C. Gallo; Wang, D. // Annals of Oncology;May2014 Supplement 1, Vol. 25 Issue suppl_1, pi27 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics